AMGEN INC
For the period ended Dec 31, 2025. Filed Feb 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 13, 2026
AMGN$465.230.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
DEFINED TERMS AND PRODUCTSii
Defined Terms and Products
Defined terms
We use several terms in this Annual Report on Form 10-K, including but not limited to those that are finance, regulation and disease-state related as well as names of other companies, which are provided below.
| Term | Description |
|---|---|
| 2017 Tax Act | Tax Cuts and Jobs Act of 2017 |
| 340B Program | Federal 340B Drug Pricing Program |
| AI | artificial intelligence |
| Amended 2009 Plan | Amended and Restated 2009 Equity Incentive Plan |
| AOCI | accumulated other comprehensive income (loss) |
| AstraZeneca | AstraZeneca plc |
| ASU | Accounting Standards Update |
| ATMOS | Amgen Technology and Medical Organizations |
| B-ALL | B-cell acute lymphoblastic leukemia |
| BeOne | BeOne Medicines Ltd. (formerly BeiGene, Ltd.) |
| BiTE® | bispecific T-cell engager |
| BLA | Biologics License Application |
| BPCIA | Biologics Price Competition and Innovation Act of 2009 |
| CCPA | California Consumer Privacy Act of 2018 |
| CDT | Cybersecurity & Digital Trust |
| CGRP | calcitonin gene-related peptide |
| ChemoCentryx | ChemoCentryx, Inc. |
| chemotherapy | anticancer medicines |
| CHMP | Committee for Medicinal Products for Human Use |
| CIO | Chief Information Officer |
| CISO | Chief Information Security Officer |
| CMS | Centers for Medicare & Medicaid Services |
| COSO | Committee of Sponsoring Organizations of the Treadway Commission |
| CRCC | Corporate Responsibility and Compliance Committee |
| DLL3 | delta-like ligand 3 |
| DOJ | U.S. Department of Justice |
| EC | European Commission |
| EMA | European Medicines Agency |
| EO | Executive Order |
| EPO | European Patent Office |
| EPS | earnings per share |
| EU | European Union |
| FASB | Financial Accounting Standards Board |
| FCPA | U.S. Foreign Corrupt Practices Act |
| FDA | U.S. Food and Drug Administration |
| FDCA | Federal Food, Drug, and Cosmetic Act |
| Fitch | Fitch Ratings, Inc. |
| GAAP | U.S. generally accepted accounting principles |
| GDPR | General Data Protection Regulation |
| GIPR | glucose-dependent insulinotropic polypeptide receptor |
| GLP-1 | glucagon like peptide 1 |
| HHS | U.S. Department of Health and Human Services |
ii
| Term | Description |
|---|---|
| Horizon | Horizon Therapeutics plc |
| IGF-1R | insulin-like growth factor-1 receptor |
| IgG4-RD | Immunoglobulin G4-related disease |
| IND | Investigational New Drug Application |
| IPR&D | in-process research and development |
| IRA | Inflation Reduction Act of 2022 |
| IRS | Internal Revenue Service |
| July MFN Letter | Letter dated July 31, 2025, by the Administration to a number of pharmaceutical manufacturers, including Amgen |
| KRAS | Kirsten rat sarcoma viral oncogene homologue |
| Kyowa Kirin | Kyowa Kirin Co., Ltd. |
| LDL-C | low-density lipoprotein cholesterol |
| MAA | Marketing Authorisation Application |
| MD&A | management’s discussion and analysis |
| MFN | Most-Favored-Nations |
| MFN EO | Most-Favored-Nations Prescription Drug Pricing Executive Order, dated May 12, 2025 |
| Moody’s | Moody’s Investors Service, Inc. |
| MRD | minimal residual disease |
| Neumora | Neumora Therapeutics, Inc. |
| NIH | National Institutes of Health |
| NOL | net operating loss |
| NSCLC | non-small cell lung cancer |
| OB3 | P.L. 119-21, also The One Big Beautiful Bill Act signed into law on July 4, 2025 |
| OECD | Organisation for Economic Co-operation and Development |
| PBM | pharmacy benefit manager |
| PCSK9 | proprotein convertase subtilisin/kexin type 9 |
| PDAB | Prescription Drug Affordability Board |
| R&D | research and development |
| RANKL | receptor activator of nuclear factor kappa-B ligand |
| RAR | Revenue Agent Report |
| RAS | Rat sarcoma viral oncogene |
| REMS | Risk Evaluation and Mitigation Strategy |
| ROU | right-of-use |
| ROW | rest of world |
| RSUs | restricted stock units |
| S&P | Standard & Poor’s Financial Services LLC |
| SEC | U.S. Securities and Exchange Commission |
| SG&A | selling, general and administrative |
| SOFR | Secured Overnight Financing Rate |
| TED | thyroid eye disease |
| Teneobio | Teneobio, Inc. |
| U.S. Treasury | U.S. Department of the Treasury |
| USPTO | U.S. Patent and Trademark Office |
| UTB | unrecognized tax benefit |
iii
Products
The brand names of our products, our delivery devices and certain of our product candidates and their associated generic names are provided below.
| Term | Description |
|---|---|
| ACTIMMUNE | ACTIMMUNE® (interferon gamma-1b) |
| Aimovig | Aimovig® (erenumab-aooe) |
| AMJEVITA/AMGEVITA | AMJEVITA® (adalimumab-atto)/AMGEVITA™ (adalimumab) |
| Aranesp | Aranesp® (darbepoetin alfa) |
| AutoTouch | AutoTouch® |
| AVSOLA | AVSOLA® (infliximab-axxq) |
| BKEMV/BEKEMV | BKEMV® (eculizumab-aeeb)/BEKEMV™ (eculizumab) |
| BLINCYTO | BLINCYTO® (blinatumomab) |
| BUPHENYL | BUPHENYL® (sodium phenylbutyrate) |
| ConfiPen | ConfiPen™ |
| Corlanor | Corlanor® (ivabradine) |
| ENBREL | Enbrel® (etanercept) |
| ENBREL Mini | ENBREL Mini® |
| EPOGEN | EPOGEN® (epoetin alfa) |
| EVENITY | EVENITY® (romosozumab-aqqg) |
| IMDELLTRA/IMDYLLTRA | IMDELLTRA® (tarlatamab-dlle)/IMDYLLTRA™ (tarlatamab) |
| IMLYGIC | IMLYGIC® (talimogene laherparepvec) |
| KANJINTI | KANJINTI® (trastuzumab-anns) |
| KRYSTEXXA | KRYSTEXXA® (pegloticase) |
| KYPROLIS | KYPROLIS® (carfilzomib) |
| LUMAKRAS/LUMYKRAS | LUMAKRAS®/LUMYKRAS™ (sotorasib) |
| MariTide | Maridebart cafraglutide (MariTide™) |
| MVASI | MVASI® (bevacizumab-awwb) |
| Neulasta | Neulasta® (pegfilgrastim) |
| NEUPOGEN | NEUPOGEN® (filgrastim) |
| Nplate | Nplate® (romiplostim) |
| Onpro | Onpro® |
| Otezla | Otezla® (apremilast) |
| Parsabiv | Parsabiv® (etelcalcetide) |
| PAVBLU | PAVBLU® (aflibercept-ayyh) |
| PENNSAID | PENNSAID® (diclofenac sodium topical solution) 2% |
| PROCYSBI | PROCYSBI® (cysteamine bitartrate) |
| Prolia | Prolia® (denosumab) |
| QUINSAIR | QUINSAIR® (levofloxacin) |
| RAVICTI | RAVICTI® (glycerol phenylbutyrate) |
| RAYOS | RAYOS® (prednisone) |
| Repatha | Repatha® (evolocumab) |
| RIABNI | RIABNI® (rituximab-arrx) |
| Sensipar/Mimpara | Sensipar®/Mimpara™ (cinacalcet) |
| SureClick | SureClick® |
| TAVNEOS | TAVNEOS® (avacopan) |
| TEPEZZA | TEPEZZA® (teprotumumab-trbw) |
iv
| Term | Description |
|---|---|
| TEZSPIRE | TEZSPIRE® (tezepelumab-ekko) |
| UPLIZNA | UPLIZNA® (inebilizumab-cdon) |
| Vectibix | Vectibix® (panitumumab) |
| WEZLANA/WEZENLA | WEZLANA® (ustekinumab-auub)/WEZENLA™ (ustekinumab) |
| XGEVA | XGEVA® (denosumab) |
Products referenced in this report that are not included in the above list are the properties of their respective owners.
v
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.